Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010 - Wikidata - wikimedia - TriplyDB

Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010

Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010

http://www.wikidata.org/entity/Q34025234

about

Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes Primer on tumor immunology and cancer immunotherapy The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects.Improving the safety of cell therapy with the TK-suicide gene Adoptive T-cell therapy: adverse events and safety switches.Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells Seatbelts in CAR therapy: How Safe Are CARS?Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation.Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future.GUCY2C-targeted cancer immunotherapy: past, present and future.Genetic engineering of T cells for the immunotherapy of haematological malignancies.Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.Advances in the development of cancer immunotherapies.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.Overcoming the toxicity hurdles of genetically targeted T cells.Gene and virotherapy for hematological malignancies Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation.Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.T-cell immunotherapy: looking forward.Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!Safety strategies of genetically engineered T cells in cancer immunotherapy.CAR-T cells: the long and winding road to solid tumors.Immunotherapy advances for mesothelioma treatment.Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.

P2860

Q24633960-37C4F81E-3FE5-44CF-8B6B-8044E9881704 Q27001126-6810C4D5-5B25-4948-BCF2-255456F2A326 Q33993529-F8A481FA-6909-4529-A269-5F4521AA326F Q34235597-3911CF77-0BCE-4EA9-9C08-2B3B1B25FCEE Q34477411-4A2E8E72-3BDB-4537-BC54-06B1265BBE23 Q34511623-56688578-862E-4AD7-9C57-E0353C1850BD Q34520155-354C12D6-1AA0-4D24-94A0-FDD01EDE690E Q35328354-A8011799-04C9-4C68-81A7-4F1A18DCF59B Q35818365-1FBF15E9-A272-4912-A896-1024E8FA7057 Q35988657-0EEE35F2-4B26-4887-91BB-C3B8476A4765 Q36390805-BA0F27DF-33B0-476D-AD1E-3FD0B00660A9 Q36682812-B82DA317-2079-427E-B86D-E65CE9623D0D Q36883904-25690B4A-C7A4-4C94-9C60-A548DF9D977B Q37436837-B96D8815-713B-4E0F-966B-A77C4FFD4A96 Q37519025-FBE8EE18-7A99-4EE1-805E-29D7D5148EBD Q37937083-BF675ED8-8B0F-4B44-9832-970D3096D57F Q37950928-30882B5C-CC9F-4475-9AA8-ADFBA5DF110D Q37965815-E87655C3-D329-4D93-90C0-55427F293F32 Q38035043-8DFF9597-4B33-45F3-B005-F2EB1F984C48 Q38049010-54E4491E-FEEC-43B4-AECB-B64BAE824312 Q38149916-6D2F7D7B-CA1F-43EE-A02F-491829841E2B Q38170501-9CB34B4B-A61D-4B26-86B5-5D0FC09379BC Q38285543-ED61D057-C2C1-420E-BE13-D78B0A76C319 Q38854625-611BFB15-C125-4A5D-8AA6-C6A130B44841 Q39104849-23EADA0C-07A9-4ED0-8C2F-5FEA32B96FFF Q39111432-94ECA5EF-BD5E-44B6-B090-35972ABC7FEE Q40167916-1A6EA9BA-5794-4E5B-8287-0C91BDD85D0C Q42427577-4B3DE99F-22AF-46F7-B5C4-7F9BEB43D3FE Q42549120-70CCED1E-FDBA-44DA-AD78-7C754D55094F Q47159409-E521906A-C3A4-45BA-A85B-1C33D40844A9 Q47289766-676B6441-F3A4-4561-A665-6AB6C0979E58 Q47667620-A4E1848B-EDF7-4AF5-A4AB-F8E1FFA930C4 Q49959264-AAD877CD-7151-4058-9BFA-77C981F2B228 Q51823843-36156A32-FA56-453F-A56F-9BC74374B55F Q52675063-5DE812BD-74CB-477B-98A3-AF446CBF05D8

P2860

Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010

http://www.wikidata.org/entity/Q34025234

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Considerations for the clinica ...... e Symposium held June 15, 2010

@ast

Considerations for the clinica ...... e Symposium held June 15, 2010

@en

Considerations for the clinica ...... e Symposium held June 15, 2010

@nl

type

label

Considerations for the clinica ...... e Symposium held June 15, 2010

@ast

Considerations for the clinica ...... e Symposium held June 15, 2010

@en

Considerations for the clinica ...... e Symposium held June 15, 2010

@nl

prefLabel

Considerations for the clinica ...... e Symposium held June 15, 2010

@ast

Considerations for the clinica ...... e Symposium held June 15, 2010

@en

Considerations for the clinica ...... e Symposium held June 15, 2010

@nl

P1433

Q34025234-33A7E9EC-50DF-4B74-AB0E-3B9860453754

P1476

Q34025234-3D297D4A-FCDA-4E47-8118-FDC36D9D7E38

P2093

Q34025234-1486BD33-F0E9-43DD-B687-4B74736C6CE9

Q34025234-2F274C96-14A4-495D-B130-C45C507D23C1

Q34025234-32574D16-8E7A-4A51-A16C-30A09D18F654

Q34025234-71CDCDD9-5ECA-4C0F-8E90-BF46AE528689

Q34025234-CEC1D0ED-6D9C-4140-A9E8-751AB73A7889

Q34025234-D588FB75-F166-459B-AEA6-F3DE306CFA72

Q34025234-E26633DD-5CE6-4996-8710-59289557F596

Q34025234-F256352C-A5C7-4F04-B865-783A4B0487D3

Q34025234-F97D2185-E2FA-43AC-A020-F713A5448BA6

P2860

Q34025234-2321D0BD-DCC6-4DCB-9034-5D5DA5539CD3

Q34025234-2A6ED36B-3C41-47E5-A958-E4E8253618CD

Q34025234-2F8EF2F7-ABAA-4148-9EFA-E8A327688D20

Q34025234-314C7B3F-846D-4CB1-8810-98754C86AF4A

Q34025234-3788A955-9CF4-4462-A46A-4D7EE2D6AD42

Q34025234-4D6DBBB4-A55F-4AC7-847A-6830F0A27A6B

Q34025234-5E72B8E3-97EB-420D-8FBE-59D13F85DB28

Q34025234-603C57D3-642B-448C-A20C-CE80DAEA9A17

Q34025234-67D52B07-0E56-498F-B9D7-8FEC5CF0EF67

Q34025234-691F2D28-4014-4496-98DF-A187B1E88A38

P304

Q34025234-64BBA233-E97C-4CBF-8BAB-6DF9275942DE

P31

Q34025234-B49A9A06-D175-49BE-B27B-FC361EC571D3

P356

Q34025234-B3BCAA80-A98D-4880-AB63-723738C1E79B

P407

Q34025234-FA943D64-FA69-4476-9A98-4E1FD68F43ED

P433

Q34025234-3D865E23-3D25-44A5-A83C-31999D995FE6

P478

Q34025234-281F08ED-9995-40FA-ACDB-837BEDBCDAAB

P577

Q34025234-AC0B974D-B3EE-4287-B364-30B2E61A40A8

P5875

Q34025234-31CC7677-8552-4637-BF46-9BE645A03A04

P698

Q34025234-3FA28781-FF5C-4E1A-BF29-BBE0341DB8B1

P932

Q34025234-4EE416C2-2B6D-4484-AC19-DEE3D93255B6

P356

0008-5472.CAN-10-4035

P1433

Cancer Research

P1476

Considerations for the clinica ...... e Symposium held June 15, 2010

@en

P2093

Carl H June

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Hildegund C J Ertl

http://www.w3.org/2001/XMLSchema#string

Jacqueline Corrigan-Curay

http://www.w3.org/2001/XMLSchema#string

Jeffrey Kahn

http://www.w3.org/2001/XMLSchema#string

John Zaia

http://www.w3.org/2001/XMLSchema#string

Laurence J N Cooper

http://www.w3.org/2001/XMLSchema#string

Scott E Strome

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression in patients after transfer of genetically engineered lymphocytes

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Gene modification strategies to induce tumor immunity.

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

P304

3175-3181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-4035

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51088019

http://www.w3.org/2001/XMLSchema#string

P698

21531763

http://www.w3.org/2001/XMLSchema#string

P932

4128091

http://www.w3.org/2001/XMLSchema#string